Communiqués Sigyn Therapeutics, Inc.

Actions

SIGY

US82674U2050

Equipement, fournitures et distribution médicale

Marché Fermé - OTC Markets Autres places de cotation 21:43:38 06/08/2026			Varia. 5j.	Varia. 1 janv.
0,0390 ^USD	+11,43%		+57,61%	-97,72%

07/05	Oragenics signe une lettre d'intention pour l'octroi d'une licence sur la technologie Cardiodialysis(TM) de Sigyn Therapeutics visant l'inflammation systémique post-traumatisme crânien	RE
07/05	Oragenics signe une lettre d'intention pour l'octroi d'une licence sur la technologie CardioDialysis de Sigyn Therapeutics ciblant l'inflammation systémique liée aux traumatismes crâniens	CI

Communiqués

02/04	Sigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTE	AQ
24/03	Scientific American Highlights Scientific Discovery That Supports the Potential Use of CardioDialysis(TM) to Treat Neuroinflammatory Diseases	AQ
14/03	Sigyn Therapeutics Issues Shareholder Update Regarding Potential Merger and Asset Sale Initiatives	AQ
15/01	Sigyn Therapeutics Issues Shareholder Update Highlighting the Advancement of CardioDialysis(TM) and New Corporate Initiatives	AQ
08/01	The Emergence of Blood Purification Devices to Treat Cardiovascular Disease	AQ
11/12	Sigyn CEO Note: First-In-Industry Attributes of CardioDialysisTM to Treat Cardiovascular Disease	AQ
03/12	Sigyn CEO Note: Nature Publication Reinforces Rationale for CardioDialysisTM to Address Cardiovascular Disease in Dialysis Patients	AQ
18/11	Sigyn CardioDialysis(TM) Featured on the Big Biz Show	AQ
14/11	Sigyn Therapeutics Reports Third Quarter Financial Results and Subsequent Introduction of CardioDialysis(TM)	AQ
07/11	Sigyn Therapeutics Releases Shareholder Letter to Introduce CardioDialysis(TM)	AQ
21/10/25	Sigyn Therapeutics, Inc. to Present at the LD Micro Main Event XIX	NE
17/10/25	Sigyn Therapeutics, Inc. to Present at the LD Micro Main Event XIX	NE
16/09/25	Sigyn Therapeutics to Present at the Life Sciences Virtual Investor Forum on September 18th	AQ
11/09/25	Sigyn Therapeutics Appoints Dr. Christoph Zaba to Its Scientific Advisory Board	AQ
03/09/25	Sigyn Therapeutics Announces Cardiovascular Disease Study	AQ
12/03/25	Sigyn CEO Note: An Emerging New Industry, 15 Years in the Making	AQ
05/03/25	Sigyn CEO Note: Combating the Rising Threat of New Pandemic Viruses	AQ
25/02/25	Sigyn Therapeutics to be Featured in Fireside Chat With Zacks Healthcare Analyst	AQ
18/02/25	Sigyn Therapeutics to Present at Tomorrow's Emerging Growth Conference	AQ
05/02/25	Sigyn Therapeutics to Present at Tomorrow’s Small Cap Growth Virtual Investor Conference	AQ
29/01/25	Sigyn Therapeutics Announces the Appointment of Michael Ryan to Its Board of Directors	AQ
07/10/24	Sigyn Therapeutics : Private Placement Form 8 K	PU
15/05/24	Sigyn Therapeutics Reports First Quarter 2024 Financial Results	AQ
07/05/24	Sigyn Therapeutics Discloses Publication of "Sigyn Therapy, an Emerging Candidate to Address Endotoxemia, Sepsis, and Drug-Resistant Viral & Bacterial Infections"	AQ
05/03/24	Sigyn Therapeutics™ to Present at Tomorrow’s Emerging Growth Conference	AQ